Peter D. Senter
- Radiology, Nuclear Medicine and Imaging top 0.05%
- Monoclonal and Polyclonal Antibodies Research 112
- Radiopharmaceutical Chemistry and Applications 16
- Oncology top 0.1%
- HER2/EGFR in Cancer Research 79
- Peptidase Inhibition and Analysis 20
- CAR-T cell therapy research 16
- Cancer Treatment and Pharmacology 14
- Immunology and Allergy top 1%
- Molecular Biology top 0.5%
- Glycosylation and Glycoproteins Research 24
- Cancer therapeutics and mechanisms 18
- Immunology top 1%
Peter D. Senter
172 papers receiving 14.4k citations
Hit Papers
Peers
Comparison fields: 5 of 131
- Radiology, Nuclear Medicine and Imaging 8.2k
- Oncology 7.8k
- Immunology and Allergy 588
- Molecular Biology 6.6k
- Immunology 2.0k
Countries citing papers authored by Peter D. Senter
This map shows the geographic impact of Peter D. Senter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter D. Senter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter D. Senter more than expected).
Fields of papers citing papers by Peter D. Senter
This network shows the impact of papers produced by Peter D. Senter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter D. Senter. The network helps show where Peter D. Senter may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peter D. Senter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 0 | |
| 4 | Antibody–drug conjugates come of age in oncologybreakdown → | 2023 | 460 |
| 5 | 2020 | 19 | |
| 6 | 2020 | 15 | |
| 7 | 2018 | 32 | |
| 8 | 2018 | 15 | |
| 9 | 2016 | 110 | |
| 10 | 2016 | 45 | |
| 11 | 2010 | 291 | |
| 12 | 2009 | 20 | |
| 13 | Trastuzumab-MC-vc-PAB-MMAF: The effects of the Drug:Antibody Ratio (DAR) on efficacy, toxicity and pharmacokinetics. | 2007 | 3 |
| 14 | Trastuzumab-Auristatin immunoconjugates inhibit growth and induce apoptosis in human breast cancer cells in vitro | 2005 | 1 |
| 15 | Tissue distribution, metabolism, and excretion of the antibody-drug conjugate Herceptin-monomethyl auristatin E in rats | 2005 | 5 |
| 16 | 2004 | 11 | |
| 17 | Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy | 2004 | 2 |
| 18 | Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate | 2004 | 0 |
| 19 | N-(4'-hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. | 1992 | 35 |
| 20 | 1979 | 1 |
About Peter D. Senter
Peter D. Senter is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Immunology and Allergy, Biotechnology and Immunology, having authored 179 papers that have together received 15.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (112 papers), HER2/EGFR in Cancer Research (79 papers), Glycosylation and Glycoproteins Research (24 papers), Peptidase Inhibition and Analysis (20 papers), Cancer therapeutics and mechanisms (18 papers), Radiopharmaceutical Chemistry and Applications (16 papers), CAR-T cell therapy research (16 papers) and Cancer Treatment and Pharmacology (14 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (8.2k citations), Oncology (7.8k citations), Immunology and Allergy (588 citations), Molecular Biology (6.6k citations) and Immunology (2.0k citations). Peter D. Senter has collaborated with scholars based in United States, Germany and Belgium. Frequent co-authors include Eric L. Sievers, Anna M. Wu, Stephen C. Alley, Damon L. Meyer, Nicole M. Okeley, Charles G. Cerveny, Svetlana O. Doronina, Alan F. Wahl, Brian E. Toki and Joseph A. Francisco. Their work appears in journals such as Bioconjugate Chemistry, Cancer Research, Clinical Cancer Research, Bioorganic & Medicinal Chemistry Letters and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.